FTV Stock Analysis: Fortive | NYSE
Scientific & Technical Instruments | NYSE, USA | Market Cap: 18.610m USD | 12M Return: 26.5% | US34959J1088 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 152M
EPS Trend: -54.0%
Qual. Beats: 0
Rev. Trend: -77.3%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Fortive Corporation (NYSE: FTV) is a large-cap industrial company that designs, develops, manufactures, and markets products, software, and services across the United States, China, and international markets. The company operates through two segments: Intelligent Operating Solutions, which offers advanced instrumentation, software, and services such as maintenance, repair, measurement, condition monitoring, and connected worker safety solutions for manufacturing, process, healthcare, utilities, and electronics industries; and Advanced Healthcare Solutions, which provides workflow solutions including instrument sterilization and tracking, biomedical test tools, radiation detection and safety monitoring, and clinical productivity software.
Fortive markets its offerings under well-known brands including FLUKE, INDUSTRIAL SCIENTIFIC, ACCRUENT, SERVICECHANNEL, GORDIAN, and INTELEX in its industrial segment, and ASP, LANDAUER, PROVATION, FLUKE BIOMEDICAL, and CENSIS in its healthcare segment. The company is classified within the Industrials sector under Industrial Machinery & Supplies & Components, reflecting its portfolio approach of acquiring and operating specialized technology businesses. Fortive was incorporated in 2015 and is headquartered in Everett, Washington, having been spun off from Danaher Corporation as an independent publicly traded company in 2016.
- Intelligent Operating Solutions revenue tracks global industrial capex cycle
- Advanced Healthcare software mix lifts recurring revenue and margins
- Accretive M&A and buybacks support earnings per share growth
| Net Income: 534.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.55 > 1.0 |
| NWC/Revenue: 7.19% < 20% (prev -1.01%; Δ 8.21% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.05b > Net Income 534.4m |
| Net Debt (3.24b) to EBITDA (1.18b): 2.75 < 3 |
| Current Ratio: 1.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (307.6m) vs 12m ago -9.98% < -2% |
| Gross Margin: 63.23% > 18% (prev 59.78%; Δ 3.45% > 0.5%) |
| Asset Turnover: 28.91% > 50% (prev 33.70%; Δ -4.79% > 0%) |
| Interest Coverage Ratio: 6.38 > 6 (EBIT TTM 786.7m / Interest Expense TTM 123.4m) |
| A: 0.03 (Total Current Assets 1.60b - Total Current Liabilities 1.29b) / Total Assets 11.6b |
| B: 0.49 (Retained Earnings 5.69b / Total Assets 11.6b) |
| C: 0.05 (EBIT TTM 786.7m / Avg Total Assets 14.9b) |
| D: 1.09 (Book Value of Equity 6.06b / Total Liabilities 5.55b) |
| Altman-Z'' = 3.27 = A |
| DSRI: 1.03 (Receivables 657.8m/912.2m, Revenue 4.32b/6.15b) |
| GMI: 0.95 (GM 59.78% / 63.23%) |
| AQI: 1.08 (AQ_t 0.84 / AQ_t-1 0.77) |
| SGI: 0.70 (Revenue 4.32b / 6.15b) |
| TATA: -0.04 (NI 534.4m - CFO 1.05b) / TA 11.6b) |
| Beneish M = -3.22 (Cap -4..+1) = AA |
As of August 22, 2026, the stock is trading at USD 60.08 with a total of 1,435,523 shares traded. Over the past week, the price has changed by -2.50%, over one month by -0.97%, over three months by +1.90% and over the past year by +26.48%.
Current recommended Stop Loss: 56.70 (which is 5.6% or 2.4 ATR below the current price).
Fortive has received a consensus analysts rating of 3.24. Therefore, it is recommended to hold FTV.
- StrongBuy: 3
- Buy: 1
- Hold: 11
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 64.3 | 7% |
P/E Trailing = 32.6032
P/E Forward = 20.5339
P/S = 4.3121
P/B = 3.0707
P/EG = 1.2896
Revenue TTM = 4.32b USD
EBIT TTM = 786.7m USD
EBITDA TTM = 1.18b USD
Long Term Debt = 3.51b USD (from longTermDebt, last quarter)
Short Term Debt = 899.5m USD (from shortTermDebt, last fiscal year)
Debt = 3.61b USD (from shortLongTermDebtTotal, last quarter) + Leases 100.6m
Net Debt = 3.24b USD (calculated: Debt 3.61b - CCE 374.2m)
Enterprise Value = 21.8b USD (18.6b + Debt 3.61b - CCE 374.2m)
Interest Coverage Ratio = 6.38 (Ebit TTM 786.7m / Interest Expense TTM 123.4m)
EV/FCF = 22.88x (Enterprise Value 21.8b / FCF TTM 954.9m)
FCF Yield = 4.37% (FCF TTM 954.9m / Enterprise Value 21.8b)
FCF Margin = 22.13% (FCF TTM 954.9m / Revenue TTM 4.32b)
Net Margin = 12.38% (Net Income TTM 534.4m / Revenue TTM 4.32b)
Gross Margin = 63.23% ((Revenue TTM 4.32b - Cost of Revenue TTM 1.59b) / Revenue TTM)
Gross Margin QoQ = 63.39% (prev 63.17%)
Tobins Q-Ratio = 1.88 (Enterprise Value 21.8b / Total Assets 11.6b)
Interest Expense / Debt = 3.42% (Interest Expense 123.4m / Debt 3.61b)
Taxrate = 10.39% (69.8m / 672.0m)
NOPAT = 705.0m (EBIT 786.7m * (1 - 10.39%))
Current Ratio = 1.24 (Total Current Assets 1.60b / Total Current Liabilities 1.29b)
Debt / Equity = 0.60 (Debt 3.61b / totalStockholderEquity, last quarter 6.06b)
Debt / EBITDA = 2.75 (Net Debt 3.24b / EBITDA 1.18b)
Debt / FCF = 3.39 (Net Debt 3.24b / FCF TTM 954.9m)
Total Stockholder Equity = 6.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.58% (Net Income 534.4m / Total Assets 11.6b)
RoE = 8.52% (Net Income TTM 534.4m / Total Stockholder Equity 6.28b)
RoCE = 8.04% (EBIT 786.7m / Capital Employed (Equity 6.28b + L.T.Debt 3.51b))
RoIC = 6.40% (NOPAT 705.0m / Invested Capital 11.0b)
WACC = 8.08% (E(18.6b)/V(22.2b) * Re(9.05%) + D(3.61b)/V(22.2b) * Rd(3.42%) * (1-Tc(0.10)))
Discount Rate = 9.05% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -96.41 | Cagr: -6.29%
[DCF] Terminal Value 73.10% ; FCFF base≈1.13b ; Y1≈993.6m ; Y5≈802.8m
[DCF] Fair Price = 31.95 (EV 12.9b - Net Debt 3.24b = Equity 9.65b / Shares 302.0m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -53.96 | EPS CAGR: -5.90% | SUE: 0.76 | # QB: 0
Revenue Correlation: -77.33 | Revenue CAGR: -10.04% | SUE: 0.07 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.71 | Chg30d=+0.13% | Revisions=+0% | Analysts=13
EPS current Year (2026-12-31): EPS=3.02 | Chg30d=+0.53% | Revisions=+53% | GrowthEPS=+11.2% | GrowthRev=+5.0%
EPS next Year (2027-12-31): EPS=3.25 | Chg30d=+0.89% | Revisions=+36% | GrowthEPS=+7.8% | GrowthRev=+4.0%
[Analyst] Revisions Ratio: +36% (up=23, down=10)